Adoptive cell therapy for Melanoma using tumour infiltrating lymphocytes: John Bridgeman
3 Visualizações
administrator
07/30/23
A look at the use of TIL in Melanoma and future TIL engineering strategies. John Bridgeman is the Director of Cell Therapy Research at Immetacyte Ltd
Mostre mais
Comentários do Facebook
Nenhum comentário encontrado